Related Experiment Video
Updated: Aug 10, 2025
Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow
Published on: May 26, 2023
Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 24-Month Period (ProgStar Report No.
Rupert W Strauss1, Alexander Ho2, Anamika Jha2
1From the Department of Ophthalmology, Medical University Graz (R.W.S.), Graz, Austria; Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, University College London (R.W.S., K.F., M.M.), London, United Kingdom; Department of Ophthalmology, Kepler University Clinic (R.W.S.), Linz, Austria; Institute of Clinical and Molecular Ophthalmology Basel (IOB) (R.W.S., H.P.N.S.), Basel, Switzerland.
Purpose:
To estimate the progression rate of atrophic lesions in Stargardt disease derived from fundus autofluorescence (FAF).
Design:
International, multicenter, prospective cohort study.
Methods:
A total of 259 participants aged ≥6 years with disease-causing variants in the ABCA4 gene were enrolled from 9 centers and followed over a 24-month period. FAF images were obtained every 6 months, and areas of definitely decreased autofluorescence (DDAF) and decreased autofluorescence (DAF) were quantified. Progression rates were estimated from linear mixed models with time as the independent variable.
Results:
A total of 488 study eyes of 259 participants (88.8% with both eyes) were enrolled and images from 432 eyes were followed for 24 months. The overall estimated progression of DDAF was 0.74 mm2/y (95% CI 0.64-0.85, P < .0001) and that of DAF was 0.64 mm2/y (95% CI 0.57-0.71) over a 24-month period in univariate analysis. Growth rates were strongly dependent on baseline lesion area. After square root transformation, the DDAF growth rate was not dependent on baseline lesion radius (P = .11), whereas the DAF growth rate was dependent (P < .0001). Genotype was not found to significantly impact the growth rate of DDAF or DAF lesions.
Conclusions:
FAF may serve as a convenient monitoring tool and suitable end point for interventional clinical trials that aim to slow disease progression. DDAF and DAF lesion sizes at baseline are strong predicting factors for lesion area growth and can be partially accounted for by square root transformation.
